31 August 2022
Notice of Interim Results
London, UK, 31 August 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), will announce its interim results for the six months ended 30 June 2022 on Thursday 8 September 2022.
A briefing open to analysts will take place remotely via Zoom on Thursday 8 September 2022 at 14.00 (BST). Analysts should contact Walbrook PR at firstname.lastname@example.org for the registration details.
CEO, Greg Madison, CFO, Hans-Peter Rudolf, and CMO, José Menoyo MD, will also be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 16.30 (BST) on Thursday 8 September 2022.
The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via: https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
Investors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.